1 September 2020 in Circulation: Arrhythmia and Electrophysiology
Background: The development of multielectrode mapping catheters has expanded the spectrum of mappable ventricular tachycardias (VTs). Full diastolic pathway recording has been associated with a high rate of VT termination during radiofrequency ablation as well as noninducibility at study end. However, the role of diastolic pathway mapping on VT recurrence has yet to be clearly elucidated. We aimed to explore the role of complete diastolic pathway activation mapping on VT recurrence. Methods: Eighty-five consecutive patients who underwent VT ablation guided by high-density mapping were enrolled. During activation mapping, the presence of electrical activity in all segments of diastole defined the evidence of having had recorded the whole diastolic interval. Patients were categorized as having recorded the full diastolic pathway, partial diastolic pathway, or no diastolic pathway map performed. Recurrences of VT were defined as appropriate implantable cardioverter defibrillator therapies or on the basis of ECG-documented arrhythmia. Results: Eighty-five patients were included. Complete recording of the diastolic pathway was achieved in 36/85 (42.4%) patients. Partial recording of the diastolic pathway of the clinical VT was achieved in 24/85 (28.2%) patients. No recording of the diastolic pathway of the clinical VT was feasible in 25/85 patients (29.4%). At a mean of 12.8 months, freedom from VT recurrence was 67% in the overall cohort. At a mean of 12.8 months, freedom from VT recurrence was 88%, 50%, and 55% in patients who had full diastolic activity recorded, partial diastolic activity recorded, or underwent substrate modification, respectively; the observed differences were statistically significant ( P =0.02). Conclusions: Mapping of the entire diastolic pathway was associated with a higher freedom from VT recurrence as compared with partial diastolic pathway recording and substrate modification. The use of multielectrode mapping catheters in recording diastolic activity may help predict those VTs employing intramural circuits and further optimize ablation strategies.
27 August 2020 in Artery Research
Background: Carotid-femoral Pulse Wave Velocity (cfPWV) is the gold-standard measure of arterial stiffness. Accuracy of non-invasive cfPWV as meters per second is impeded by surface estimates of aortic length. Our aim was to compare cfPWV measured using distance estimated from surface measurements with distance traced along the length of the aorta using Magnetic Resonance Imaging (MRI) in a cohort of older women. Methods: Seventy-four women were recruited from the TwinsUK cohort. cfPWV was measured using the SphygmoCor system (SphygmoCor-PWV). The path between carotid and femoral sites was estimated from surface measurements between the sternal notch and femoral artery applanation point. Aortic distance was measured with MRI to obtain MRI-PWV. cfPWV was recalculated using MRI obtained distance. Results: Mean ± standard deviation SphygmoCor-PWV was 9.9 ± 2.1 m/s and MRI-PWV 7.63 ± 1.97 m/s (mean difference 2.2 ± 1.96 m/s, p < 0.001). Distances were considerably higher using surface measures for the SphygmoCor (55.2 ± 3.0, 95% confidence interval 54.4–55.9 cm) compared with MRI (39.9 ± 3.2, 39.2–40.7 cm) with a mean difference of 15.2 cm (14.3–16.2 cm, p < 0.001). Transit times were also marginally longer with the SphygmoCor. When SphygmoCor-PWV was Recalculated using MRI-obtained aortic distance (rec-PWV), the difference between SphygmoCor-PWV and rec-PWV reduced to 0.5 m/s (7.13 ± 1.46 vs. 7.63 ± 1.97 m/s, p = 0.08). Conclusion: In these older women, the PWV difference between SphygmoCor and MRI is substantial but reduced when using MRI length estimates. Important differences between PWV measured by Sphygmocor and MRI are mainly due to accuracy of distance measurements, which may need re-addressing in guidelines.
21 April 2026 in Journal of the American Heart Association
Background: Severe aortic stenosis (AS) is associated with ischemic stroke independently of atrial fibrillation or other causes. Even after aortic valve replacement (AVR), patients remain affected by a 6% 5‐year stroke rate with knowledge gaps in the underlying pathophysiology. We hypothesize that severe AS is associated with prothrombotic left atrial (LA) flow changes that do not normalize after AVR. Methods: Seventy‐seven participants without atrial fibrillation were recruited: 40 with severe AS (median age, 73 years; CHA 2 DS 2 VASc score, 3) and 37 controls with similar risk profile (median age, 71 years; CHA 2 DS 2 VASc score, 3). All underwent baseline cardiac magnetic resonance imaging. Among the 40 patients with AS, 23 (58%) underwent AVR and repeat cardiac magnetic resonance imaging ≈6 months after surgery. Results: Compared with controls, patients with severe AS displayed significantly higher left ventricular (LV) mass ( P =0.04), smaller LV volumes ( P =0.01), and reduced global longitudinal strain ( P <0.001). Although LA volume was within the normal range and LA emptying fraction was not different from controls, severe AS was associated with lower LA peak flow velocity (mean, 0.25 versus 0.28 m/s, respectively; P =0.02) and lower LA flow vorticity (mean, 16.6 versus 21.1 radians; P <0.001) compared with controls. AVR led to regression of LV hypertrophy with LV mass that was no longer different from controls ( P =0.32). Nevertheless, post‐AVR patients displayed a persistent adverse morpho‐functional phenotype characterized by persistently lower velocity (mean, 0.24 versus 0.28 m/s; P =0.003) and vorticity (17.1 versus 21.1 radians; P <0.001) compared with controls. Conclusions: Patients with severe AS display adverse prothrombotic LA flow characteristics that persist after successful AVR despite general regression of LV hypertrophy.